Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle Biosciences (CSTL) has scheduled the release of its first quarter 2025 financial results for Monday, May 5, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results.
The live webcast will be accessible through the company's investor relations website and a dedicated event link. Participants can join via phone by dialing 1 833 470 1428 from the United States using access code 040892. International dial-in numbers are available. A Q&A session will follow management's presentation, and a webcast replay will be provided after the call.
Castle Biosciences (CSTL) ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per lunedì 5 maggio 2025, dopo la chiusura del mercato. L'azienda ospiterà una teleconferenza e una trasmissione in diretta alle 16:30, ora orientale, per discutere i risultati.
La trasmissione in diretta sarà accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda e un link dedicato all'evento. I partecipanti possono unirsi per telefono componendo il numero 1 833 470 1428 dagli Stati Uniti utilizzando il codice di accesso 040892. Sono disponibili numeri di accesso internazionali. Una sessione di domande e risposte seguirà la presentazione della direzione e una registrazione della trasmissione sarà fornita dopo la chiamata.
Castle Biosciences (CSTL) ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el lunes 5 de mayo de 2025, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica y una transmisión web a las 4:30 p.m., hora del Este, para discutir los resultados.
La transmisión en vivo será accesible a través del sitio web de relaciones con inversores de la empresa y un enlace dedicado al evento. Los participantes pueden unirse por teléfono marcando el 1 833 470 1428 desde Estados Unidos utilizando el código de acceso 040892. También hay números de acceso internacional disponibles. Una sesión de preguntas y respuestas seguirá a la presentación de la dirección y se proporcionará una repetición de la transmisión después de la llamada.
캐슬 바이오사이언스(CSTL)는 2025년 1분기 재무 결과를 2025년 5월 5일 월요일, 시장 종료 후 발표할 예정입니다. 회사는 결과를 논의하기 위해 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 것입니다.
실시간 웹캐스트는 회사의 투자자 관계 웹사이트와 전용 이벤트 링크를 통해 접근할 수 있습니다. 참가자는 미국에서 1 833 470 1428로 전화하여 액세스 코드 040892를 사용하여 참여할 수 있습니다. 국제 전화 번호도 제공됩니다. 경영진의 발표 후 Q&A 세션이 진행되며, 통화 후 웹캐스트 재생이 제공될 것입니다.
Castle Biosciences (CSTL) a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le lundi 5 mai 2025, après la clôture du marché. L'entreprise organisera un appel conférence et un webinaire à 16h30, heure de l'Est, pour discuter des résultats.
Le webinaire en direct sera accessible via le site web des relations investisseurs de l'entreprise et un lien dédié à l'événement. Les participants peuvent se joindre par téléphone en composant le 1 833 470 1428 depuis les États-Unis en utilisant le code d'accès 040892. Des numéros d'appel internationaux sont également disponibles. Une session de questions-réponses suivra la présentation de la direction, et une rediffusion du webinaire sera fournie après l'appel.
Castle Biosciences (CSTL) hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Montag, den 5. Mai 2025, nach Börsenschluss geplant. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen.
Der Live-Webcast wird über die Investor-Relations-Website des Unternehmens und einen speziellen Veranstaltungslink zugänglich sein. Teilnehmer können sich telefonisch unter 1 833 470 1428 aus den USA einwählen und den Zugangscode 040892 verwenden. Internationale Einwahlnummern sind ebenfalls verfügbar. Eine Frage- und Antwortsitzung wird der Präsentation des Managements folgen, und eine Aufzeichnung des Webcasts wird nach dem Anruf bereitgestellt.
- None.
- None.
FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025.
Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.
To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 040892. International dial-in numbers are available here: https://www.netroadshow.com/conferencing/global-numbers?confId=80251; please use the same access code above to join the call.
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When will Castle Biosciences (CSTL) release Q1 2025 earnings?
What time is Castle Biosciences (CSTL) Q1 2025 earnings call?
How can investors access CSTL's Q1 2025 earnings call?
Will there be a Q&A session during CSTL's Q1 2025 earnings call?
